scispace - formally typeset
O

Orly Dym

Researcher at Weizmann Institute of Science

Publications -  81
Citations -  6321

Orly Dym is an academic researcher from Weizmann Institute of Science. The author has contributed to research in topics: Biology & Protein structure. The author has an hindex of 31, co-authored 69 publications receiving 5269 citations.

Papers
More filters
Journal ArticleDOI

Kemp elimination catalysts by computational enzyme design

TL;DR: The computational design of eight enzymes that use two different catalytic motifs to catalyse the Kemp elimination—a model reaction for proton transfer from carbon—with measured rate enhancements of up to 105 and multiple turnovers are described.
Journal ArticleDOI

Protein production and purification.

Susanne Gräslund, +86 more
- 01 Feb 2008 - 
TL;DR: This review presents methods that could be applied at the outset of any project, a prioritized list of alternate strategies and a list of pitfalls that trip many new investigators.
Journal ArticleDOI

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

TL;DR: The production of a recombinant human GCD in a carrot cell suspension culture shows a level of biological activity similar to that of Cerezyme produced in CHO cells, as well as a highly homologous high-resolution three-dimensional structure, determined by X-ray crystallography, indicating the potential safety of prGCD.
Journal ArticleDOI

Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability.

TL;DR: A computational strategy is developed and designed an AChE variant bearing 51 mutations that improved core packing, surface polarity, and backbone rigidity and obtained enhanced stability and/or higher yields of soluble and active protein in E. coli.
Journal ArticleDOI

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.

TL;DR: It is shown that the high-affinity variant RBD-62 can be used as a drug to inhibit infection with SARS-CoV-2 and variants Alpha, Beta and Gamma in vitro and its structure provides a structural basis for future drug and vaccine development and for in silico evaluation of known antibodies.